Dr. Suresh R D

Brief Profile

Dr. Suresh R D is an experienced pediatrician with 6 years of clinical practice, including 5 years as a consultant.

He has significant expertise in pediatric hematology-oncology and is knowledgeable about innovative diagnostic techniques and management strategies. Dr. Suresh demonstrates extensive experience in bone marrow transplantation, as well as in pediatric emergency and critical care.

Dr.Suresh is committed to providing high-quality care to his patients and continually seeks opportunities for advancement in pediatric medicine.

Educational Qualifications

• MBBS, Government Mohan Kumaramangalam Medical College, Salem, 2002 – 2007
• Internship, Government Mohan Kumaramangalam Medical College, Salem, 2007 –  2008
• MD Paediatrics, JSS Medical College, Mysore, 2013 – 2016 
• Fellowship in Paediatric Hematology Oncology, Apollo Specialty Hospital, Chennai, 2022 – 2024

Clinical Expertise

• Bone Marrow Transplantation
  
• Pediatric Hematology and Oncology
  
• Pediatric Emergency and Critical Care
  
• Diagnostic Assessments

Honors and Awards

• Second Prize for ‘Real World Data on Relapsed Acute Lymphoblastic Leukemia from South India,’ RGCON 2023.
  

Research and Publication

• Real World Data on Childhood Relapsed Acute Lymphoblastic Leukemia: A Report of 100 Children Over 2 Decades from Southern India, Journal of Indian Pediatrics, August 1, 2024.

Paper Presentations

• HSCT and Vaccine Related Infections in Children with IEI, APSID 2023.
  
• An Increasing Trend of Adenoviral Infection in Children Undergoing Alternate Donor HSCT, APBMT 2023.
  
• 10-Year Follow-Up Study of Children with Thalassemia Post HSCT with Impact on Growth and Puberty, APBMT 2023.
• Optimizing Outcome of Children Undergoing Haplo HSCT for Thalassemia Major with Anti-HLA Antibodies, APBMT 2023.
• Real World Data of Relapsed Acute Lymphoblastic Leukemia from South India, RGCON 2023.

Poster Presentations

• Miss of Opportunity Due to Opportunistic Disease in X-Linked SCID, APSID 2023.
• Inferior Outcomes in Melphalan– Based Conditioning Compared with Busulfan and Fludarabine in Children Undergoing HSCT, ISBMT 2023.
• Inotuzumab with Ponatinib for Remission Induction in Children with Ph Positive ALL Early Results from Tertiary Referral Centre, India, RGCON 20233.
• Twenty-Year Follow-Up on Importance of Diagnostic Cytogenetics on Outcome in Children Treated as per UKMRC AML Protocol, ISBMT 2023.

Experience

• Medical Officer at Primary Health Centre, Kolli Hills, Sep 2011 – Mar 2013
  
• Senior Registrar at Karpagam Medical College, Coimbatore, Sep 2016 – Sep 2017
  
• Consultant Pediatrician at Masonic Children’s Hospital, Coimbatore, Oct 2017 – Dec 2021
  
• Registrar at Pediatric Hematology-Oncology Apollo Specialty Hospital, Chennai, Jan 2024 – Jul 2024